Conclusion: The extremely impressive performance of DRE and PSA as diagnostic and screening tools may be due to the limitation of the study to a cohort of patients who already hard lower urinary tract symptoms. There is need for community based studies.Irekpita...
通过多元逻辑回归分析结果显示,本研究中PV(≥56 mL vs.<56 mL)、年龄(≥67岁 vs.<67岁)、MRI(结节阳性 vs.结节阴性)和DRE(结节阳性 vs.结节阴性)均可作为独立的前列腺穿刺阳性率的影响因素,其OR值分别为4.941(P=0.012)、5.947(P=0.007)、6.010(P=0.023)、39.424(P=0.000)。进一步将PV、年龄、MRI、DRE...
Objective To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer–specific mortality. Design, Setting, and Participants The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) included 419 582 men ...
Prostate-specific antigen (PSA) is a commonly used test to detect prostate cancer. Attention has mostly focused on the use of PSA in screening asymptomatic patients, but the diagnostic accuracy of PSA for prostate cancer in patients with symptoms is less
First, because a recent study has defined tPSA thresholds for identifying or excluding advanced PCa, as an aid to personalize management of the diagnostic workup, by using well calibrated risk prediction models and tPSA results exclusively obtained by Roche assay [13]. Noteworthy, most of ...
Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Further well designed studies are urgently needed to clarify if use of prostate-specific antigen (PSA) as a diagnostic test for prostate cancer can ...
Second, to establish whether measures taken during the diagnostic process could be used to identify those men for whom focal therapy would be a suitable treatment of their prostate cancer. Third, to detail the pathological characteristics of tumours suitable for focal ablation. PATIENTS AND METHODS ...
基于SEER数据库研究局部治疗对低PSA、高Gleason评分的前列腺癌患者预后的影响一、摘要(一)中文摘要背景:前列腺癌,主要是前列腺腺癌,是美国男性泌尿系统最常见的恶性肿瘤之一,也是美国肿瘤相关死亡的主要原因。近年来,我国前列腺癌患者的发病率和死亡率逐年攀升,已成为困扰我国中老年男性的重大健康问题。最新研究显示,低...
Diagnostic performance of the predictive model Analysis of ROC curves showed that the AUC for PSA was 0.585 (95%CI: 0.447–0.724) (Table 4). More powerful univariate independent predictor associated with CSPCa risk was 68Ga-PSMA PET/CT (AUC = 0.850), which was higher than that of PSA...
Other studies have shown that men with PSA values in this range have only about a 30% to 35% chance of being found to have a cancer upon biopsy. This poor diagnostic specificity is one of the leading problems related to PSA testing. ...